SPIRO-2102

N/A

Report date: 2024/01/02 17:41:49

Base Information

Drug NameSPIRO-2102
Drug Alias NameSPIRO-2102
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionCystic fibrosis transmembrane conductance regulator modulatorsGene transference
TargetsCystic fibrosis transmembrane conductance regulator
Therapy Area/IndicationsCystic Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSpirovant Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesSumitomo Dainippon Pharma Co Ltd
Inactive CompaniesN/A
Active IndicationsCystic Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A